First Human Trial for ALS Treatment Candidate AT-1501 Begins Dosing

First Human Trial for ALS Treatment Candidate AT-1501 Begins Dosing

Anelixis Therapeutics has begun dosing patients in the first human trial of its amyotrophic lateral sclerosis (ALS) treatment candidate, AT-1501, the company announced.

The trial is currently enrolling both healthy volunteers and eight ALS patients to test AT-1501’s safety and tolerability. Researchers will also examine how the agent behaves inside the body, including its metabolism and excretion.

“[The] dosing of the first person with ALS is a significant milestone in determining the potential utility of this approach in battling back this horrific disease,” Steve Perrin, PhD, president and CEO of Anelixis Therapeutics, said in a press release.

AT-1501 is an investigational antibody that targets the CD40 ligand (CD40L), a protein present at the surface of some white blood cells that is involved in inflammation. In ALS, the CD40L protein is produced in excess and is thought to be involved in neurodegeneration.

AT-1501 was developed by the ALS Therapy Development Institute (ALS TDI), with support from several ALS organizations, including the ALS Association, ALS ONE, and ALS Finding a Cure.

Last week, the ALS Association announced it had awarded Anelixis an additional $1 million to help fund the trial.

“We are proud to partner with Anelixis and other ALS organizations to help advance this promising compound into clinical trials,” said Calaneet Balas, president and CEO of the ALS Association. “Through this new funding, we are continuing our support of novel, early-stage potential treatments into human clinical trials.”

“We are excited to work closely with Anelixis to accelerate bringing AT-1501 to people with ALS,” said Merit Cudkowicz, director of the Healey Center for ALS at Massachusetts General Hospital, and chief medical officer for ALS Finding a Cure.

“The support from other ALS organizations for this trial has been crucial to its successful launch,” said Steve Perrin, who also serves as the president & CEO of the ALS Therapy Development Institute.

The results of the Phase 1 trial, if positive, will support a subsequent Phase 2a study to further evaluate AT-1501’s safety and tolerability, and other clinical parameters, such as potential biomarkers.

“The ALS ONE-supported trial design team members at the Healey Center are already working together with Anelixis to design the next trial to assess longer-term safety and efficacy. It is critical to move faster from exciting lab-based scientific discovery to clinical trials in our patients,” Cudkowicz said.

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
×
Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • NPT520-34 orphan drug status
  • genetic cause
  • RPS25 gene
  • gut microbiome

16 comments

  1. Kelly says:

    How do healthy people get involved in this trial. I lost my husband to ALS and would love to assist in the testing of potentially life saving treatments.

  2. Kathy Templeton says:

    My son-in-law has ALS he’s an ex football player for Ohio State University in the NFL. He raises money for ALS through Ohio State and donations that people give. I would like to get him into this trial as soon as possible. I would like a return text or call at 614-633-6527 and please if I do not answer leave a message and identify yourself and give me a number or a email address something that I can contact you with. I think you could benefit very much by it. Please reply thank you my name is Kathy Templeton and again my phone number is 614-633-6527 his name is William White and we live in Columbus Ohio actually we live in Powell Ohio but it’s right outside of Columbus.

  3. Heidi Maurice says:

    My sister has ALS since October 2017 . She took Rilutek and also the injections Edaravone since August 2018 – no improvment she is worth than before . how can i help her

  4. nina m says:

    I contacted Dr. Peter Weis in Nigeria for the treatment of my father’s illness through the Internet. Dr. Weis said, “I need $500 to send you a herbal remedy” and told me “do not worry my child”. I sent him money, but I never received any medication. About his scam I warn all ALS patients. He also has a fake certificate, which I later found out it was a big lie. Please note that he does not have any medication for ALS.

  5. Jane Erway says:

    How does one apply for this treatment? Is it currently available as Iunderstand it is past the trial phase so what is next? When will it be available for people with ALS,my daughter has it and we need to find help as do many many others who have been left behind in research for ALS because there is no big money in it for the drug companies. Sad that money comes before lives in this country where money is wasted every minute.

Leave a Comment

Your email address will not be published. Required fields are marked *